Maslah et al. found that the synergistic effects of APR-246 with 5-azacitidine in TP53-mutated MDS and AML were mediated by downregulation of the FLT3 pathway in drug-treated cells [109]. Here, TP53 is linked to myelodysplastic syndrome.